DxS
Designs and develops personalised medicines
Sector
Lifesciences
Location
Manchester
Deal type
Growth Capital
Investment size
Undisclosed - 15.7x return
The business
- A designer and developer of personalised medicines
- Supplies the pharmaceutical industry with crucial biomarkers and companion diagnostics for use in the development of cancer fighting drugs
- A management buy out from pharmaceutical giant, AstraZeneca
The strategy
- Grow market share rapidly via strategic partnerships
- Widen the offering of products and services for use in clinical drug testing
- Continue innovation by investing in new product pipeline and via commercial partnerships
The developments
- Successfully developed and brought to market the world’s first companion diagnostic
- Increased the value of the business by 11x in the first five years since initial investment
- Sold to Qiagen generating a 15.7x return for YFM funds
Back to top